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that the clinical isolate and the larvae 
from the Paciﬁ  c cod were identiﬁ  ed 
as P. azarasi, 1 of 2 species found in 
water near Japan. Adult worms live in 
the intestines of seals and sea lions, 
and infective larvae live in the tissues 
of various marine ﬁ  sh, including cod, 
pollack, and smelt (1). 
In Japan, most patients infected 
with  Pseudoterranova spp. have 
acute or subacute abdominal pain, and 
larvae are extracted from the stomach 
endoscopically. However, for some 
patients, diagnosis is made when 
4th-stage larvae are expelled from 
the mouth, indicating that the larvae 
developed from the 3rd to 4th stage 
during the time of infection, as did 
the worm reported here. Expulsion of 
Pseudoterranova spp. larvae from the 
mouth in the absence of severe gastric 
symptoms occurs more commonly 
in Chile (5). Whether the varied 
symptoms triggered by infection with 
Pseudoterranova spp. larvae reﬂ  ect 
different responses of individual 
hosts to the worms or whether the 
pathogenicity of Pseudoterranova 
spp. in humans differs among worm 
species remains to be elucidated. 
Because of the increasing 
worldwide popularity of eating sushi 
and sashimi made of raw marine ﬁ  sh, 
consumers should be made aware 
of the possible risk for ﬁ  sh-borne 
parasitoses. Freezing and storing 
ﬁ  sh at −20°C for 7 days or freezing 
at  −35°C until solid and storing at 
−35°C for 15 hours is sufﬁ  cient to kill 
parasites (6).
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Mycobacterium 
mageritense 
Pulmonary Disease 
in Patient with 
Compromised 
Immune System
To the Editor:  Mycobacterium 
mageritense is one of the rapidly 
growing mycobacteria (RGM). It 
was ﬁ  rst isolated in Spain in 1987, 
described as a new species in 1997 
by Domenech et al. (1), and ﬁ  rst 
described and associated with 
disease in the United States in 2002 
(2). In the 2002 report, 6 isolates 
were recovered from sputum, a 
bronchoscopy sample, a wound 
infection after liposuction, the blood 
of an immunosuppressed patient with 
a central catheter and sepsis, a patient 
with severe sinusitis, and from a 
wound infection in a patient who had 
probable osteomyelitis after ﬁ  xation 
of an open fracture. It has since 
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Figure. Phylogenetic analysis of members of Pseudoterranova decipiens species complex 
roundworms. Genetic relationships between NADH dehydrogenase subunit 1 sequences 
in clinical and Paciﬁ  c cod isolates and species were inferred by using the neighbor-joining 
method. Bootstrap values (1,000 replicates) are shown next to the branches. The ﬁ  nal 
dataset contained 498 positions.  *P. decipiens sensu stricto. Scale bar indicates nucleotide 
substitutions per site. LETTERS
been reported as a cause of water-
related skin and soft tissue infections 
(3,4). A study from Japan in 2007 
reported recovery of M. mageritense 
from the sputum of a woman 
with noncaseating granulomas by 
transbronchial biopsy who improved 
without therapy (5). We describe a 
case of M. mageritense pneumonia in 
an immunocompromised patient. 
In 2009, a 54-year-old woman 
was admitted to the hospital in Austin, 
Texas, with a 5-day history of upper 
back pain and occasional hemoptysis 
and yellow sputum production. 
She had a long history of systemic 
lupus erythematosus and associated 
nephritis and vasculitis, rheumatoid 
arthritis, hypothyroidism, sleep apnea, 
and hepatitis C infection. She was 
taking prednisone 15 mg/day at the 
time of admission.
Five months earlier, organizing 
pneumonia was diagnosed in the 
patient by computed tomography–
guided lung biopsy of a pleura-based 
mass; special stains and cultures on 
tissue for acid-fast bacilli (AFB), other 
bacteria, and fungi were negative. 
She was readmitted several times 
over subsequent months and treated 
with various antimicrobial agents 
and corticosteroids but did not show 
clinical or radiographic improvement. 
Chest computed tomographic scan 
performed at admission again 
demonstrated bilateral lung masses 
and inﬁ   ltrates, with new areas of 
necrosis. A second needle biopsy 
sample showed chronic inﬂ  ammation 
with a histiocytic reaction and 
negative stains for AFB and fungi, 
but it was deemed nondiagnostic. 
Subsequent open lung biopsy sample 
showed necrotizing granulomatous 
inﬂ   ammation with possible vascular 
involvement suggestive of Wegener 
granulomatosis.
Fite staining showed rare clusters 
of AFB within the granulomas. The 
postoperative course was complicated 
by a multiloculated left pleural effu-
sion. AFB smear of pleural ﬂ  uid 
obtained from video-assisted thora-
coscopy showed 1–5 bacilli per high 
power ﬁ  eld. Cultures of  lung tissue 
and pleural ﬂ  uid grew mycobacteria 
initially identiﬁ  ed  as  M. fortuitum 
group but subsequently identiﬁ  ed as 
M. mageritense by PCR followed by 
restriction enzyme analysis of the 65-
kDa heat-shock protein (hsp65) (6). 
Results of susceptibility testing by 
broth microdilution are shown in the 
Table.
Testing for Wegener granulo-
matosis by antineutrophilic cyto-
plasmic and myeloperoxidase anti-
body yielded negative results. 
Imipenem and amikacin were 
prescribed, and gradual resolution 
of clinical signs and symptoms 
was observed. Oral linezolid and 
trimethoprim/sulfamethoxazole were 
prescribed at discharge. Chest radio-
graphs taken 4 months after the open 
lung biopsy showed resolution of the 
masses.
The isolate was a nonpigmented 
RGM that matched the American Type 
Culture Collection (Manassas, VA, 
USA) type strain and 10 published 
clinical isolates of M. mageritense 
by PCR restriction enzyme analysis 
of the 65-kDa hsp gene (6). By gene 
sequencing of region V of the RNA 
polymerase (rpoB) gene, it exhibited 
99.7% identity to the GenBank type 
strain sequence of M. mageritense 
(acceptable interspecies relatedness 
for this sequence is >98.5% identity) 
(8). The most closely related species 
determined by using this sequence 
and previously submitted sequences 
were other M. fortuitum species: M. 
porcinum (94% sequence identity), M. 
wolinskyi (94%), and M. peregrinum 
(93%).
Susceptibility testing of 23 
clinical isolates of M. mageritense 
from the United States previously 
submitted to the Mycobacteria/Nocar-
dia Research Laboratory (University 
of Texas Health Science Center, 
Tyler, TX, USA) and identiﬁ  ed  by 
hsp65 PCR restriction analysis (6,7) 
was performed (Table). These results 
conﬁ  rmed the potential utility of the 
drugs used in this case for future cases.
M. mageritense has not been 
reported as a cause of pulmonary 
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Table. In vitro activity of 23 isolates of Mycobacterium  mageritense, United States, 2009* 
Antimicrobial agent
No. isolates 
tested 
MICs of current 
isolate, ȝg/mL 
Intermediate 
breakpoint, ȝg/mL 
MIC range, 
ȝg/mL 
MIC50, 
ȝg/mL 
MIC90, 
ȝg/mL %  S/I 
Amikacin 23  8  32  <1–32 16  32  100 
Cefoxitin 23  16  32–64  <8–256 32  64  91 
Ciprofloxacin 23  0.25  2  <0.25–0.5 0.25  0.5  100 
Clarithromycin† 23  8  4  1–>64  >32  >64  4 
Doxycycline 22  1  2–8  0.25–>64  8  >32  50 
Imipenem 22  4  8  <0.5–8 2  4  100 
Linezolid 22  4  16  <2–16 4  8  100 
Sulfamethoxazole 21  4  32  <2–32 8  32  100 
Trimethoprim/sulfamethoxazole 6  1/19  2/38‡  <0.25/4.8– 2/38  0.5/9.5  2/38  100 
Tobramycin 23  <2 8  2–64  >16  >32  30 
Tigecycline 5  0.12  –§  <0.03–0.12 0.06  0.12  NA 
*Includes 6 isolates previously reported (2). S, susceptible; I, intermediate; NA, not available.  
†Three days’ incubation. 
‡Proposed breakpoint (7). 
§No Clinical and Laboratory Standards Institute breakpoints established for tigecycline. LETTERS
disease in an immunocompromised 
patient. However, most cases of M. 
fortuitum pneumonia were reported 
before the use of molecular technology 
for species identiﬁ  cation.  Newer 
species such as M. mageritense 
resemble M. fortuitum and would not 
have been differentiated without this 
method.
Our patient met the criteria 
for diagnosing nontuberculous 
mycobacterial lung disease as 
established by the American 
Thoracic Society and the Infectious 
Diseases Society of America (9). Her 
therapeutic response also supports a 
cause-and-effect relationship.
The identity of an RGM isolate 
as M. mageritense may be suspected 
by its unusual antimicrobial drug 
susceptibility pattern, which showed 
an intermediate MIC to amikacin 
and resistance to clarithromycin at 
3 days (Table). However, deﬁ  nitive 
identiﬁ   cation requires molecular 
methods. Previous studies have 
shown that M. mageritense contains 
an inducible erythromycin methylase 
gene (erm 40) that confers macrolide 
resistance (10). The use of molecular 
studies and greater attention to 
susceptibility patterns should 
enable increased recognition of M. 
mageritense as a human pathogen. 
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Bridge, and Ravikiran Vasireddy for 
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Extensively 
Drug-Resistant 
Tuberculosis, China 
To the Editor: The prevalence 
of drug-resistant tuberculosis (TB) 
is a serious problem in the People’s 
Republic of China. China is 1 of 22 
countries with the highest incidence 
of TB (1). It is also 1 of 27 countries 
with the highest incidence of 
multidrug-resistant TB (MDR TB) 
and extensively drug-resistant TB 
(XDR TB). According to the national 
baseline survey on TB in 2007 and 
2008, the frequency of MDR TB 
among pulmonary TB patients in 
China was 8.3%. We estimate that 
there are 120,000 new cases of MDR 
TB in China per year, which accounts 
for 24.0% of new cases worldwide 
(510,000) per year.
XDR TB has recently emerged as 
a global public health problem (2). It is 
deﬁ  ned as TB with resistance to at least 
isoniazid, rifampin, a ﬂ  uoroquinolone, 
and 1 of 3 injectable second-line drugs 
(amikacin, kanamycin, or capreo-
mycin). XDR TB is a type of MDR 
TB that shows resistance to isoniazid 
and rifampin. Recent reports on current 
prevalence of XDR TB (3,4) indicate 
that China now has the second highest 
incidence of MDR TB worldwide. 
However, there is no information 
available on XDR TB in China.
To obtain information on XDR 
TB in China, we conducted a study 
558  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011